title: Manufacturing challenges in the commercial production of recombinant coagulation factor VIII.
abstract: Advances in gene technology have led to the development of a method to manufacture recombinant coagulation Factor VIII (rFVIII) for haemophilia A. Because rFVIII is a large and complex protein, its commercialization has required that many challenges in manufacturing, purification and processing be overcome. In order to license the first generation of rFVIII (Kogenate) in 1993, Bayer Corporation invested over 10 years in research and manufacturing development. Seven additional years were subsequently devoted to research and manufacturing improvements in order to accomplish the recent licensing of a second rFVIII product (KOGENATE Bayer or Kogenate FS). This product differs from its predecessor, in that human albumin is removed from the purification and the formulation steps. In addition, fewer chromatography steps are involved resulting in greater yields per mL of conditioned medium, and a solvent-detergent viral inactivation step replaces the heat-processing step used for the previous product. Despite these changes in the manufacturing, the protein backbone and carbohydrate structure of the final rFVIII molecule are identical. The complexity of the production processes is reflected by over 100 000 manufacturing data entries and by 600 quality control tests for each batch of rFVIII. Manufacturers are continuing to develop the next generation of rFVIII, which will be produced without the addition of any human or animal proteins or byproducts. Investments in research, development and manufacturing technology are expected to result in the development of new products with enhanced safety profiles, and in an increase in the production capacity for products that are chronically in short supply.
authors.affiliation: Bayer Corporation Pharmaceutical Division, Research Triangle Park, NC, USA.
authors.forename: R
authors.initials: R
authors.lastname: Jiang
authors.forename: T
authors.initials: T
authors.lastname: Monroe
authors.forename: R
authors.initials: R
authors.lastname: McRogers
authors.forename: P J
authors.initials: PJ
authors.lastname: Larson
mesh_terms: D015195:Drug Design; D005169:Factor VIII / Q000592:standards; D005285:Fermentation; D006801:Humans; D011786:Quality Control; D012015:Reference Standards; D013678:Technology, Pharmaceutical / Q000458:organization & administration* / Q000592:standards / Q000639:trends
chemical_list: C078147:F8 protein, human; D005169:Factor VIII